Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Progressive Supranuclear Palsy: early-phase trial registry
5 of 20 indexed Progressive Supranuclear Palsy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 5 currently recruiting · #848 of 28,707 conditions by registered trial count
Progressive Supranuclear Palsy: 20 US clinical trials tracked, 5 recruiting.
Progressive Supranuclear Palsy is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 2 of these trials.
Enrollment posture brief
Registry condition progressive-supranuclear-palsy
OPEN 5 | RECR 25% | LATE 1 | EARLY 5 | RANK #848 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Progressive Supranuclear Palsy lists 5 open slots (25% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Progressive Supranuclear Palsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Progressive Supranuclear Palsy is recruiting below its size-band peers.
5 of 20 indexed trials (25%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Progressive Supranuclear Palsy trials is spread across many organizations.
Massachusetts General Hospital accounts for 2 of 20 trials (10%). 19 distinct sponsors appear on at least one study for this condition label.
-
Typical Progressive Supranuclear Palsy enrolment sits around 146 participants.
Median target enrolment is 146 among the 19 trials that report a genuine target (sentinel values excluded). 6 of those (31.6%) plan for fewer than 100 participants.
-
Progressive Supranuclear Palsy splits between interventional and observational designs.
12 interventional and 8 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Modifiable Variables in Parkinsonism (MVP)
Bastyr University
NCT02194816
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
National Institute of Neurological Disorders and Stroke (NINDS)
NCT03225144
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
Mayo Clinic
NCT02605785
Gait Analysis in Neurological Disease
Beth Israel Deaconess Medical Center
NCT02994719
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
University of Texas Southwestern Medical Center
NCT03872102
Trial of Parkinson's And Zoledronic Acid
California Pacific Medical Center Research Institute
NCT03924414
Community Outreach for Palliative Engagement -- Parkinson Disease
University of Rochester
NCT05222386
Automated Imaging Differentiation of Parkinsonism
University of Florida
NCT05913687
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Ferrer Internacional S.A.
NCT06355531
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
University of Michigan
NCT05459753
AMX0035 and Progressive Supranuclear Palsy
Amylyx Pharmaceuticals
NCT06122662
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
Massachusetts General Hospital
NCT04753320
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
Massachusetts General Hospital
NCT05956834
Art Therapy in Progressive Supranuclear Palsy
Vanderbilt University Medical Center
NCT06588673
Speech Accessibility Project
University of Illinois at Urbana-Champaign
NCT05889260
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Allon Therapeutics
NCT01110720
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Noscira
NCT01049399
In-Home Care for Patients With PSP and Related Disorders
Rush University Medical Center
NCT03552484
Young Plasma Transfusions for Progressive Supranuclear Palsy
University of California, San Francisco
NCT02460731
Effects of Coenzyme Q10 in PSP and CBD
Lahey Clinic
NCT00532571
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Progressive Supranuclear Palsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Progressive Supranuclear Palsy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Progressive Supranuclear Palsy page
20 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Progressive Supranuclear Palsy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Progressive Supranuclear Palsy trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Progressive Supranuclear Palsy condition card totals 20 registered trials; most-linked intervention Placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.